Related Experiment Video
Updated: Feb 5, 2026

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
Aaron Kithcart1,2, Calum A MacRae1,2
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract:
Cardiovascular diseases remain a major challenge for modern drug discovery. The diseases are chronic, complex, and the result of sophisticated interactions between genetics and environment involving multiple cell types and a host of systemic factors. The clinical events are often abrupt, and the diseases may be asymptomatic until a highly morbid event. Target selection is often based on limited information, and though highly specific agents are often identified in screening, their final efficacy is often compromised by unanticipated systemic responses, a narrow therapeutic index, or substantial toxicities. Our understanding of complexity of cardiovascular disease has grown dramatically over the past 2 decades, and the range of potential disease mechanisms now includes pathways previously thought only tangentially involved in cardiac or vascular disease. Despite these insights, the majority of active cardiovascular agents derive from a remarkably small number of classes of agents and target a very limited number of pathways. These agents have often been used initially for particular indications and then discovered serendipitously to have efficacy in other cardiac disorders or in a manner unrelated to their original mechanism of action. In this review, the rationale for in vivo screening is described, and the utility of the zebrafish for this approach and for complementary work in functional genomics is discussed. Current limitations of the model in this setting and the need for careful validation in new disease areas are also described. An overview is provided of the complex mechanisms underlying most clinical cardiovascular diseases, and insight is offered into the limits of single downstream pathways as drug targets. The zebrafish is introduced as a model organism, in particular for cardiovascular biology. Potential approaches to overcoming the hurdles to drug discovery in the face of complex biology are discussed, including in vivo screening of zebrafish genetic disease models.
Insights
Cardiovascular disease drug discovery faces challenges due to disease complexity. Zebrafish models offer a promising in vivo screening approach for identifying novel therapeutic targets and overcoming limitations in current cardiovascular medicine.
Area of Science:
- Cardiovascular Biology
- Drug Discovery
- Genomics
Background:
- Cardiovascular diseases (CVDs) are complex, multifactorial conditions posing significant challenges to modern drug discovery.
- Current CVD treatments often derive from a limited number of drug classes targeting few pathways, with efficacy issues due to systemic responses or toxicities.
- Despite advances, understanding of CVD complexity has grown, revealing new potential disease mechanisms.
Purpose of the Study:
- To review the rationale and utility of in vivo screening for cardiovascular drug discovery.
- To discuss the application of zebrafish as a model organism for cardiovascular research and functional genomics.
- To explore approaches for overcoming drug discovery hurdles in complex cardiovascular diseases.
Main Methods:
- Review of existing literature on cardiovascular drug discovery and model organisms.
- Discussion of in vivo screening methodologies, particularly in zebrafish.
- Analysis of functional genomics approaches in cardiovascular research.
Main Results:
- Zebrafish offer a valuable platform for in vivo screening and functional genomics in cardiovascular biology.
- In vivo screening in zebrafish genetic models can help identify novel therapeutic targets and pathways.
- Limitations of current models and the need for rigorous validation in new disease areas are highlighted.
Conclusions:
- The complexity of cardiovascular diseases necessitates innovative drug discovery approaches beyond targeting single pathways.
- Zebrafish models provide a powerful tool for in vivo screening and advancing cardiovascular drug discovery.
- Further validation of zebrafish models is crucial for translating findings to clinical applications.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Assessment of the Cardiovascular System II: Inspection
Head and Neck
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...

